ClinicalTrials.gg
WithdrawnNCT01953536Updated Dec 19, 2014

Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

A Phase 2 interventional study of Vintafolide 2.5 mg and Paclitaxel 80 mg/m^2 in Breast Neoplasms, sponsored by Endocyte. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-19.

Sponsored by Endocyte (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
350th of 361
0 · median 60
Started
2014
with 11 others
Phase 2
205 of 373
20 open now
Registered
244th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 350th largest by enrollment of the 361 interventional ones that give a count, is one of 12 that started in 2014, is one of 205 in phase 2, and was the 244th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of vintafolide alone compared to vintafolide plus paclitaxel and paclitaxel alone in participants with with 100% positive folate receptor (FR) triple negative breast cancer (TNBC).

The primary hypothesis of this study is the vintafolide alone and/or vintafolide + paclitaxel will improve progression free survival (PFS) in participants with FR (100%) TNBC compared to paclitaxel alone.

Read the detailed description

During the screening stage, participants will be required to have a diagnostic computed tomography (CT) scan with etarfolatide (EC20) to identify target lesions and determine eligibility for treatment. After successful screening, during the treatment stage, participants will receive study drug (vintafolide, vintafolide + paclitaxel, or paclitaxel) for approximately four 28-day cycles.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female with or cytologically confirmed estrogen receptor negative, progesterone receptor negative, human epidermal growth factor receptor 2 () negative advanced breast cancer that is or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
  • Has developed progressive disease following at least 1 (and not more than 4) prior chemotherapeutic regimens for breast cancer, which was administered for treatment of locally advanced, locally recurrent and/or metastatic disease. [At least 1 regimen must have included a taxane (e.g., paclitaxel, docetaxel) in any combination or order.]
  • Has at least a single measurable target lesion on a radiological evaluation that is conducted no more than 4 weeks prior to beginning of study drug. ( should not have received prior radiation therapy.)
  • Has not received chemotherapy for 4 weeks prior to the initiation of study drug and must have recovered to ≤ (CTCAE) grade 1 toxicities related to prior chemotherapies.
  • Female participants of should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug.
  • Female participants of childbearing potential should be willing to use 2 methods of or be surgically sterile, or abstain from heterosexual activity for the course of the study through 30 days after the last dose of study drug.
  • Has an (ECOG) performance status of 0 or 1.
  • Has no history of a prior with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin or has undergone potentially curative therapy with no evidence of that disease for 5 years.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has had chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies) within 4 weeks prior to study drug administration or has not recovered (≤Grade 1 or baseline) from adverse experiences due to agents administered more than 4 weeks earlier.
  • Is currently participating or has participated in a study with an compound or device within 28 days of initial dosing on this study.
  • Has received more than 4 prior cytotoxic regimens for disease. treatments would not count towards this criterion.
  • Has a primary central nervous system (CNS) tumor.
  • Has active and/or carcinomatous meningitis.
  • Has had prior therapy with vinorelbine (Navelbine®) or vinca-containing compounds.
  • Has known to paclitaxel, docetaxel, other taxane therapies, drugs formulated with polyoxyethylated castor oil (Cremophor EL®), vinblastine, other vinca derived therapies, or their components or analogs.
  • Has pre-existing neuropathy >Grade 2.
  • Has a recent (i.e., ≤6 weeks) history of abdominal surgery or peritonitis.
  • Has a bowel occlusion or sub-occlusion.
  • Has had prior abdominal or pelvic radiation therapy, or radiation therapy to >10% of the bone marrow at any time in the past, or prior radiation therapy within the last 3 years to the breast/sternum, dermal lesions, head, or neck.
  • Requires anti-folate therapy.
  • Has known psychiatric or substance abuse disorders.
  • Is a known regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
  • Is expecting to reproduce within the projected duration of the study, and women who are pregnant or breastfeeding.
  • Is known to be (HIV)-positive.
  • Has known active or C.
  • Has symptomatic ascites or pleural effusion.
  • Has had a prior stem cell or bone marrow transplant.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vintafolide

    Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.

    Drug: Vintafolide 2.5 mg · Drug: Etarfolatide · Drug: Folic acid

  • Experimental
    Vintafolide + Paclitaxel

    Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.

    Drug: Vintafolide 2.5 mg · Drug: Paclitaxel 80 mg/m^2 · Drug: Etarfolatide · Drug: Folic acid · Drug: Premedication for Paclitaxel

  • Active comparator
    Paclitaxel

    Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.

    Drug: Paclitaxel 80 mg/m^2 · Drug: Etarfolatide · Drug: Folic acid · Drug: Premedication for Paclitaxel

Interventions

  • During treatment, participants receive IV vintafolide 2.5 mg.

  • DrugPaclitaxel 80 mg/m^2

    Drug page: Paclitaxel

    During treatment, participants receive IV paclitaxel 80 mg/m\^2.

  • DrugEtarfolatide

    During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.

  • During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.

  • DrugPremedication for Paclitaxel

    During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time frame: Up to 60 months

Secondary outcomes

  1. Objective Response Rate (Complete Response [CR] + Partial Response [PR])

    Time frame: Up to 60 months

  2. Clinical Benefit Rate (CR + PR + Stable Disease [SD] for >=6 months)

    Time frame: Up to 60 months

  3. Overall Survival (OS)

    Time frame: Up to 60 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2013
First posted
Oct 1, 2013
Start
Apr 2014
Primary completionEst.
Nov 2016
CompletionEst.
Nov 2016
Last update
Dec 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01953536
Lead sponsor
Endocyte
Responsible party
Sponsor
First posted
Oct 1, 2013
Start date
Apr 2014
Primary completion
Nov 2016 (estimated)
Completion
Nov 2016 (estimated)
Last update
Dec 19, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EC145 · Paclitaxel

Start the discussion